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 Mast cells limit extracellular levels of IL-13 via 
a serglycin proteoglycan-serine protease axis 
 Abstract :  Mast cell (MC) granules contain large amounts of 
proteases of the chymase, tryptase and carboxypeptidase 
A (MC-CPA) type that are stored in complex with serglycin, 
a proteoglycan with heparin side chains. Hence, serglycin-
protease complexes are released upon MC degranulation 
and may influence local inflammation. Here we explored the 
possibility that a serglycin-protease axis may regulate levels 
of IL-13, a cytokine involved in allergic asthma. Indeed, we 
found that wild-type MCs efficiently degraded exogenous 
or endogenously produced IL-13 upon degranulation, 
whereas serglycin −/− MCs completely lacked this ability. 
Moreover, MC-mediated IL-13 degradation was blocked 
both by a serine protease inhibitor and by a heparin antago-
nist, which suggests that IL-13 degradation is catalyzed by 
serglycin-dependent serine proteases and that optimal 
IL-13 degradation is dependent on both the serglycin and 
the protease component of the serglycin-protease complex. 
Moreover, IL-13 degradation was abrogated in MC-CPA −/− 
MC cultures, but was normal in cultures of MCs with an 
inactivating mutation of MC-CPA, which suggests that the 
IL-13-degrading serine proteases rely on MC-CPA protein. 
Together, our data implicate a serglycin-serine protease axis 
in the regulation of extracellular levels of IL-13. Reduction of 
IL-13 levels through this mechanism possibly can provide a 
protective function in the context of allergic inflammation. 
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 Introduction 
 Mast cells (MCs) are multifunctional cells with the capac-
ity to regulate immune responses, in addition to their 
role as effector cells during inflammatory conditions 
and infections (Galli et al. , 2008 ). MCs operate through 
a wide variety of bioactive mediators that they release in 
response to activation by, for example, Fc ɛ RI crosslinking 
(Lundequist and Pejler , 2011 ). Proteases are stored in 
exceedingly high amounts in the secretory granules of 
MCs, and they are released as fully active enzymes upon 
degranulation (Pejler et al. , 2007 ). MC proteases could 
therefore have a profound influence on local inflamma-
tory reactions. However, the exact contribution of indi-
vidual proteases in disease progression under various 
inflammatory settings is only beginning to be uncovered 
(Pejler et al. , 2010 ; Caughey , 2011 ). Based on their cleav-
age specificity, MC proteases can be divided into three 
main groups: chymases, tryptases and MC carboxypepti-
dase A (MC-CPA; CPA3) [reviewed in (Pejler et al. , 2007, 
2009b )]. 
 We recently demonstrated that a murine chymase, 
mouse MC protease (mMCP)-4, protects against bronchial 
hyperreactivity and airway inflammation in a model of 
allergic airway inflammation (Waern et al. , 2009 ). This is 
intriguing considering that MCs, as such, are detrimental 
in the context of allergic disease (Bradding et al. , 2006 ; 
Galli et al. , 2008 ; Feyerabend et al. , 2011 ), and suggests 
that released MC proteases may have a down-regulatory 
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impact on the otherwise pro-inflammatory potential of 
MCs. The exact mechanism by which MC proteases confer 
protection in this allergic model is not known. However, a 
plausible scenario is that chymase and/or other MC pro-
teases may regulate the course of an inflammatory reac-
tion through proteolytic action on bioactive proteins, such 
as cytokines. 
 IL-13 is a key cytokine known to play a vital role in 
the development of allergic airway responses, e.g., by its 
ability to induce IgE production, bronchial hyperreactiv-
ity, eosinophil infiltration and mucus production (Grunig 
et al. , 1998 ; Wills -Karp et al., 1998 ; Zhu et al. , 1999 ). 
Moreover, elevated levels of IL-13 have been found in 
human asthmatics, and polymorphisms in the IL-13 gene 
are correlated to asthma susceptibility (Humbert et al. , 
1997 ; Vercelli , 2008 ). IL-13 is predominantly expressed by 
type-2 T helper cells but can also be expressed by other 
cell types, including MCs (Toru et al. , 1998 ; Gessner 
et al. , 2005 ). 
 The storage and activities of MC proteases are, to 
a large extent, influenced by serglycin (Pejler et al. , 
2009a ; Kolset and Pejler , 2011 ), a proteoglycan species 
composed of a small protein core to which strongly 
negatively charged side chains of heparin (or chon-
droitin sulfate) type are attached. Primarily, serglycin 
proteoglycans are known to serve as storage matrices 
for several of the MC proteases, including mMCP-4, 
mMCP-5, mMCP-6 and MC-CPA, as shown by the absence 
of these proteases in MCs from serglycin-deficient mice 
( Å brink et al., 2004 ). In addition, several reports show 
that serglycin (or purified heparin) can enhance the 
actual activity of the MC proteases, either by promoting 
protease assembly (Hallgren et al. , 2004 ) or by facilitat-
ing MC protease-catalyzed cleavage of certain substrates 
(Pejler and Sadler , 1999 ; Tchougounova and Pejler , 
2001 ). However, the release of MC proteases may occur 
independently of serglycin proteoglycan, at least during 
an  in vivo response to parasite infection (Sawesi et al. , 
2010 ). 
 To explore the ability of a putative serglycin-protease 
axis to regulate IL-13 levels, we used peritoneal cell-
derived MCs (PCMCs) from a number of mouse strains 
that were deficient in either serglycin or in various ser-
glycin-dependent MC proteases. We demonstrated that 
Fc ɛ RI-activated PCMCs can efficiently degrade both exog-
enously added and endogenously produced IL-13. More-
over, the data suggest that IL-13 degradation is mediated 
by serglycin-dependent serine proteases and that optimal 
proteolytic cleavage requires that the proteases are com-
plex-bound to heparin, with heparin representing the 
functional entity of serglycin. 
 Results 
 Phenotype of cultured peritoneal MCs 
 To obtain mature MCs expressing high levels of proteases, 
we used peritoneal cell-derived MCs (PCMCs) cultured for 
4 weeks in medium containing stem cell factor (SCF) as 
described by Malbec et al.  (2007) . Wild-type (WT) MCs dis-
played typical MC phenotypes as shown by intense meta-
chromatic staining (Figure  1 A), surface expression of c-kit 
and Fc ɛ RI (Figure 1B) and the presence of MC-specific pro-
teases, i.e., mMCP-4, -5, -6 and MC-CPA (Figure 1C). Earlier 
studies have shown that mMCP-4, -5, -6 and MC-CPA are 
strictly dependent on serglycin for their storage in secre-
tory granules (Henningsson et al. , 2002 ;  Å brink et al., 2004 ; 
Henningsson et al. , 2006 ), and here we demonstrate the 
absence of these proteases in serglycin −/− PCMCs (Figure 
1C). Genetic deficiency of either mMCP-4 or mMCP-6 did 
not substantially affect levels of other MC proteases in 
PCMCs, whereas MC-CPA-deficiency was accompanied by 
a total lack of mMCP-5, as expected due to the known inter-
dependency of these proteases for proper storage (Feyera-
bend et al. , 2005 ; Younan et al. , 2010 ). Normal morphol-
ogy and staining properties were seen in PCMCs derived 
from mMCP-4 −/− , mMCP-6 −/− , MC-CPA −/− and MC-CPAmut 
(mice with an inactivating mutation in the active site of 
MC-CPA) (Figure 1A). However, as serglycin −/− PCMCs lack 
the negatively charged glycosaminoglycans (heparin) 
binding to cationic dyes, these cells displayed no meta-
chromatic staining of secretory granules (Figure 1A). 
 MC-mediated reduction of IL-13 
is serglycin-dependent 
 Next, we used PCMC cultures to explore the possibility 
that MC proteases regulate extracellular IL-13 levels. The 
processing of exogenously added IL-13 was studied in WT 
and serglycin −/− PCMC cultures in which MC degranula-
tion was induced by either IgE receptor crosslinking or 
with a calcium ionophore (A23187). At 4 h after degranu-
lation, there was already a substantial (77 % ) decrease in 
IL-13 levels in WT MC cultures, whereas levels of IL-13 were 
essentially unaltered in control wells containing non-stim-
ulated MCs or medium alone (Figure  2 ). In contrast to WT 
MCs, degranulated serglycin −/− MCs were unable to reduce 
the amount of IL-13, and high levels of IL-13 remained in 
the supernatant, even after 24 h (Figure 2). These find-
ings demonstrate that MCs can efficiently reduce external 
IL-13 upon degranulation and that this process is totally 
dependent on the presence of serglycin proteoglycan. 
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 Figure 1   Phenotypic characterization of peritoneal cell-derived MCs (PCMCs). 
 (A) PCMCs stained with May-Gr ü nwald/Giemsa (MGG,  upper panel ) or toluidine blue (TB,  lower panel ) display altered morphology in 
serglycin −/− mice and normal morphology in mMCP-4 −/− , mMCP-6 −/− , MC-CPA −/− and MC-CPAmut mice. (B) Confirmation of MC phenotype of 
WT PCMCs by flow cytometry. Expression of c-kit (CD117) and Fc ɛ RI ( thick lines ) are shown together with corresponding isotype controls 
( thin lines ). (C) Western blot analyses of protease content of PCMCs from WT, mMCP-4 −/− , mMCP-6 −/− , MC-CPA −/− , MC-CPAmut and serglycin −/− 
mice. Samples added to each well correspond to 2.7x10 3 cells, and  β -actin was used as a loading control. 
 Figure 2   IL-13 degradation by PCMCs is serglycin-dependent. 
 Degranulation of WT or serglycin −/− PCMCs was induced by IgE-
anti-TNP and OVA-TNP (IgE/Ag; A) or by calcium ionophore A23187 
(B) in the presence of IL-13. Levels of IL-13 in the supernatant were 
measured with ELISA at 1 h, 4 h and 24 h after stimulation. Data 
are expressed as means  ±  SEM (n  =  3). ***,  p  <  0.001 for stimulated 
vs. non-stimulated WT cultures, and (*),  p  <  0.05; (***),  p  <  0.001 for 
stimulated WT vs. stimulated serglycin −/− cultures. 
 Proteolytic cleavage of IL-13 by MC serine 
proteases 
 To investigate whether the MC-mediated reduction of 
IL-13 is due to proteolytic cleavage and, if so, to identify 
the type of enzyme involved, we used a panel of enzyme 
inhibitors, including Pefabloc SC (serine proteases), EDTA 
(metalloproteases), E-64 (cysteine proteases) and Pepsta-
tin A (aspartic acid proteases). Incubation with the serine 
protease inhibitor effectively blocked IL-13 degradation 
after MC activation with either IgE receptor crosslinking 
or calcium ionophore (Figure  3 ). In contrast, inhibitors 
of metalloproteases, cysteine proteases and aspartic acid 
proteases were unable to prevent IL-13 reduction (Figure 3). 
These results suggest that the reduction of IL-13 levels is 
due to proteolytic activities mediated by serglycin-depend-
ent serine proteases released upon MC degranulation. 
 Degradation of external IL-13 is abrogated 
in MC-CPA −/− MC cultures 
 The inability of serglycin −/− MCs to degrade IL-13 (Figure 2) 
implicated the serglycin-dependent proteases, i.e., 
mMCP-4, -5, -6 or MC-CPA (Pejler et al. , 2010 ). To analyze 
this further, we measured IL-13 degradation in cultures of 
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PCMCs from mice lacking individual proteases (see Figure 
1C). PCMCs were generated from mMCP-4 −/− , mMCP-6 −/− , 
MC-CPA −/− and MC-CPAmut mice, and the levels of exog-
enously added IL-13 were measured at 1 h, 4 h and 24 h 
post-stimulation. Given that Pefabloc SC could inhibit 
IL-13 degradation (Figure 3), we considered two of the 
major serine proteases, i.e., mMCP-4 and mMCP-6, to be 
likely candidates exerting the proteolytic cleavage of IL-13. 
Upon IgE crosslinking, both mMCP-4 −/− and mMCP-6 −/− 
PCMCs degraded IL-13, at least to the same extent as did 
WT cells (Figure  4 A and B), which indicates that efficient 
processing of IL-13 can occur, even in the absence of either 
of these two enzymes. Notably, non-stimulated WT cells 
exhibit a weak IL-13-degrading activity that is significantly 
reduced in the absence of mMCP-4 (Figure 4A). 
 Next, we assessed the role of MC-CPA in the degra-
dation of IL-13. As shown in Figure 4C and D, MC-CPA −/− 
MCs had a severely diminished capacity to degrade IL-13, 
whereas MC-CPAmut MCs degraded IL-13 almost as effi-
ciently as WT MCs. Moreover, Western blot analyses dem-
onstrated a dramatic decrease in the amount of visible 
IL-13 upon treatment of WT MCs with IgE and antigen, 
 Figure 3   IL-13 degradation by PCMCs is serine protease-dependent. 
Degranulation of PCMCs was induced by IgE-receptor crosslinking 
(IgE/Ag; A) or by calcium ionophore A23187 (B) in the presence of 
IL-13 and inhibitors of serine proteases (Pefabloc SC), metallopro-
teases (EDTA), cysteine proteases (E-64) or aspartic acid proteases 
(Pepstatin A). Levels of IL-13 in supernatants 24 h after degranula-
tions were measured by ELISA. Data are expressed as means  ±  SEM. 
*,  p  <  0.05; **,  p  <  0.01 for cultures with inhibitor vs. no inhibitor. 
whereas no reduction in IL-13 levels was seen for acti-
vated MC-CPA −/− MCs (Figure 4E). Altogether, these find-
ings indicate that the degradation of IL-13 is dependent 
on the presence of MC-CPA protein. However, the pre-
served IL-13 degradation seen in MCs from MC-CPAmut 
mice indicates that proteolytic activity of MC-CPA is not 
required. The latter notion was also supported by the 
inability of a metalloprotease inhibitor to prevent IL-13 
degradation (Figure 3). 
 Endogenously produced IL-13 is reduced 
in MC-CPA −/− and mMCP-4 −/− MCs 
 MCs exhibit the capacity to endogenously express and 
secrete IL-13 (Toru et al. , 1998 ; Gessner et al. , 2005 ), and 
we hypothesized that proteolytic cleavage of endogenous 
IL-13 by MC proteases could represent a means for intrin-
sic regulation. To explore this possibility, we analyzed 
IL-13 levels in cultures of Fc ɛ RI-activated MCs (without 
adding exogenous IL-13). We found that the amounts of 
endogenously produced IL-13 were significantly higher 
in cultures of Fc ɛ RI-activated MC-CPA −/− MCs compared 
to the IL-13 levels in cultures of WT or MC-CPAmut MCs 
(Figure  5 A and B), which suggests a role for MC-CPA 
protein in the degradation of endogenous IL-13. Moreover, 
there was a significantly higher amount of endogenous 
IL-13 in mMCP-4 −/− MC cultures than in WT cultures 4 h 
after degranulation (Figure 5B). By contrast, the levels of 
IL-13 mRNA, as measured by qPCR, were not higher in acti-
vated MC-CPA −/− or mMCP-4 −/− MCs, than in corresponding 
WT MCs (data not shown). Thus, our data suggests that 
both MC-CPA and mMCP-4 are involved in the regulation 
of endogenously produced IL-13 and that the regulation of 
IL-13 levels occurs at the protein- rather than at the tran-
scriptional level. 
 Recombinant mMCP-5 does not reconstitute 
IL-13 degradation by MC-CPA −/− MCs 
 Previous studies have shown that the absence of MC-CPA 
protein (MC-CPA −/− ) leads to a secondary loss of mMCP-5 
at the protein level (mMCP-4 and mMCP-6 storage is unaf-
fected), whereas mMCP-5 storage is preserved in MC-CPA-
mut MCs (Feyerabend et al. , 2005 ; Schneider et al. , 2007 ). 
This, together with the known dependence of mMCP-5 on 
serglycin for storage (Younan et al. , 2010 ), strongly impli-
cated mMCP-5 (or other MC-CPA-dependent proteases) in 
the degradation of IL-13 by activated MCs. We therefore 
assessed the capacity of recombinant mMCP-5 to degrade 
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 Figure 4   Degradation of exogenous IL-13 is abrogated in MC-CPA −/− PCMC cultures. PCMCs from mMCP-4 −/− (A), mMCP-6 −/− (B), MC-CPA −/− 
(C – E) or MC-CPAmut mice (C, D) and from their WT controls were degranulated by IgE-crosslinking (IgE/Ag) or by calcium ionophore (A23187) 
in the presence of IL-13. Levels of IL-13 in the supernatant at 1 h, 4 h and 24 h after stimulation were measured with ELISA (A – D) or Western 
blot analysis (E). Data are from representative experiments and are expressed as means  ±  SEM (n  =  3). *,  p  <  0.05; **,  p  <  0.01; ***,  p  <  0.001 
for stimulated vs. non-stimulated cultures or control medium. (*),  p  <  0.05; (***),  p  <  0.001 for differences between stimulated cultures from 
various mouse strains as indicated. 
IL-13. Enzymatic activity of purified recombinant mMCP-5 
was first confirmed by the cleavage of four different 
recombinant protein substrates (Andersson et al. , 2009 ). 
Three of them were elastase substrates containing either 
valine, isoleucine or alanine in the cleavable position 
(VLL V SEVL, VLL I SEVL, VLL A SEVL). The fourth substrate 
was a chymase substrate containing a phenyl alanine in 
the cleavable position (VLL F SEVL). The N or C terminal 
of the cleavable amino acids was based on an extensive 
phage display analysis of the rat counterpart of mMCP-5 
(rMCP-5) (Karlson et al. , 2003 ). mMCP-5 cleaved both the 
valine and isoleucine substrates very well, the alanine 
substrate between 5 and 10 times less efficiently and 
no cleavage was seen with the chymase substrate. This 
confirms the activity of the recombinant mMCP-5 enzyme 
and the elastase specificity (Kunori et al. , 2002 ). However, 
recombinant mMCP-5 at the same concentration failed to 
degrade recombinant IL-13 (Figure  6 A). MC proteases nor-
mally operate in close contact with the heparin chains of 
serglycin proteoglycan. To mimic this situation, we added 
heparin to facilitate proteolytic cleavage by mMCP-5. 
However, even in the presence of heparin, there was no 
detectable IL-13 degradation by mMCP-5 (not shown). 
Moreover, purified mMCP-5 added to PCMCs was unable 
to restore the loss of IL-13 degradation in MC-CPA −/− cul-
tures (Figure 6B). 
 In addition to mMCP-4, -5, and -6, murine MCs may store 
and release significant amounts of other serine proteases, 
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 Figure 5   Degradation of endogenous IL-13 is deficient in MC-CPA −/− and mMCP-4 −/− PCMC cultures. 
 PCMCs from MC-CPA −/− , MC-CPAmut or mMCP-4 −/− mice and from their respective WT controls were degranulated by IgE crosslinking (IgE/Ag) 
or by calcium ionophore A23187, and levels of endogenously produced IL-13 were analyzed by ELISA up to 24 h after stimulation. Data are from 
representative experiments and are expressed as means  ±  SEM (n  =  3). (A) **,  p  <  0.01; ***,  p  <  0.001 vs. WT cultures and (**),  p  <  0.01; (***), 
 p  <  0.001 for MC-CPA −/− vs. MC-CPAmut. (B) * , p  <  0.05; **,  p  <  0.01; ***,  p  <  0.001 vs. non-stimulated controls and (*),  p  <  0.05 for differences 
between stimulated cultures from various mouse strains as indicated. 
e.g., granzyme B and cathepsin G, of which granzyme B has 
been shown to be stored in a serglycin-dependent manner 
(Grujic et al. , 2005 ). To explore whether any of these pro-
teases have a role in the serglycin/MC-CPA-dependent 
degradation of IL-13, we investigated whether recombinant 
granzyme B or human cathepsin G could degrade IL-13. 
Whereas granzyme B did not cause any detectable IL-13 
degradation, human cathepsin G caused an almost com-
plete loss of added IL-13 (Figure  7 A), the latter result being 
in agreement with previous findings (Zhao et al. , 2005 ). 
These results suggested that cathepsin G expressed by the 
PCMCs may be a candidate protease mediating the sergly-
cin/MC-CPA-dependent degradation of IL-13. To evaluate 
this possibility, we first examined whether cathepsin G is 
expressed by PCMCs and if its storage is serglycin- and/
or MC-CPA-dependent. On Western blot analysis, a band 
corresponding to cathepsin G was clearly detectable in 
PCMCs from WT, mMCP-4 −/− and MC-CPAmut mice, but 
was virtually absent in MC-CPA −/− PCMCs (Figure 7B). In 
serglycin −/− PCMCs, only a faint band corresponding to 
full-size cathepsin G was observed along with the presence 
of a lower molecular weight band, the latter possibly cor-
responding to partially degraded cathepsin G (Figure 7B). 
These data suggest that cathepsin G is expressed by PCMCs 
and that it is stored in a serglycin- and MC-CPA-dependent 
fashion, i.e., an expression pattern mimicking that of the 
putative serglycin- and MC-CPA-dependent IL-13-degrading 
proteases. To further examine this, we assessed the effect 
of a cathepsin G inhibitor on PCMC-mediated IL-13 degra-
dation. However, cathepsin G inhibition using an inhibitor 
of the human enzyme failed to block PCMC-mediated IL-13 
degradation. Notably though, human and murine cath-
epsin G differ substantially within their respective active 
sites, human cathepsin G having dual trypsin- and chymo-
trypsin-like activity, whereas murine cathepsin G has sole 
chymotrypsin-like activity (Raymond et al. , 2010 ). Thus, we 
cannot exclude that the available inhibitor of human cath-
epsin G has poor efficacy towards the murine counterpart, 
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 Figure 6   Recombinant mMCP-5 does not degrade IL-13. 
 (A; left part) Recombinant murine IL-13 (1  μ g) was incubated for 
3 h with recombinant mMCP-5 (0.4  μ g), followed by SDS-PAGE and 
staining of the gel with Coomassie brilliant blue. (A; right part) 
To ascertain that mMCP-5 was enzymatically active, recombinant 
mMCP-5 (0.08  μ g) was incubated with four different recombinant 
substrates for 3 h followed by SDS-PAGE and Coomassie brilliant 
blue staining. Three of the four were elastase substrates containing 
either valine, isoleucine or alanine in the cleavable position (VLL-
VSEVL, VLLISEVL, VLLASEVL). The fourth substrate was a chymase 
substrate containing a phenylalanine in the cleavable position 
(VLLFSEVL). The valine- and isoleucine-containing substrates were 
partly cleaved, confirming the elastase activity of mMCP-5. The 
alanine-containing substrate was cleaved 5 – 10 times less effi-
ciently, whereas the phenyalanine-containing substrate, indicating 
chymase activity, was not cleaved. (B) MC-CPA −/− or WT PCMCs were 
degranulated by IgE crosslinking (IgE/Ag) in the presence of IL-13, 
and in the presence or absence of recombinant mMCP-5 (4  μ g/ml). 
Levels of IL-13 in the supernatant 24 h after stimulation were ana-
lyzed by ELISA. Data are from representative experiments and are 
expressed as mean  ±  SEM (n  =  3). 
and thus we cannot completely rule out that IL-13 is, in fact, 
degraded by PCMC-expressed (murine) cathepsin G. 
 IL-13-degrading activity is partly cell-bound 
and requires functional heparin 
 Upon MC degranulation, the released proteases may 
either remain attached to the cell surface or diffuse into 
the supernatant. To identify whether the proteolytic acti-
vity was cell surface-bound or not, we isolated cell-free 
supernatants from cultures of degranulated MCs, and the 
ability of these supernatants to degrade IL-13 was com-
pared with that of intact cultures (containing both cells 
and supernatant). Although IL-13 was degraded to some 
extent in cell-free supernatants, the degradation was most 
pronounced in whole cultures, which indicates that the 
proteases responsible for cleavage of IL-13 are localized 
partly to the cell surface (Figure  8 A). 
 Optimal MC-dependent IL-13 degradation 
requires heparin 
 Several reports suggest that MC proteases are dependent 
on interaction with heparin (or other strongly negatively 
charged glycosaminoglycans) for optimal proteolysis of 
certain substrates (Pejler and Sadler , 1999 ; Tchougounova 
et al. , 2001 ; Tchougounova and Pejler , 2001 ). To investi-
gate the role of heparin (as part of the serglycin proteogly-
can) in MC-mediated degradation of IL-13, we added the 
heparin antagonist protamine to MC cultures. Addition of 
protamine to MC cultures degranulated with IgE  + antigen 
inhibited IL-13 degradation in a dose-dependent manner 
(Figure 8B). Protamine also blocked IL-13 degradation in 
cultures stimulated with calcium ionophore, but had no 
effect on IL-13 levels when added to non-stimulated cells 
or to cell-free medium. These results suggest that prote-
olysis of IL-13 by MC serine proteases is dependent on the 
heparin side chains attached to the serglycin protein core. 
 Discussion 
 MC proteases are released as mature enzymes in high 
amounts upon Fc ɛ RI- crosslinking, and they may exert 
both beneficial and detrimental activities depending 
on the specific context. Here, we show that a serglycin 
proteoglycan-serine protease axis, unleashed by Fc ɛ RI-
activation of peritoneal cell-derived MCs, mediates effi-
cient degradation of both endogenously produced and 
exogenously added IL-13. Importantly, the data indicate 
that serglycin (heparin) contributes to the degradation 
mechanism not only by promoting the actual storage of 
the IL-13-degrading proteases, but also by presenting IL-13 
to the executioner protease. 
 Murine MCs can be cultured  in vitro using various pro-
tocols, of which bone-marrow-derived MCs have been most 
widely used. However, in the present investigation, we 
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used PCMCs as these cells display a more mature pheno-
type and express higher levels of granule-stored proteases 
(Malbec et al. , 2007 ). We confirmed the mature features 
of PCMCs as described earlier (Malbec et al. , 2007 ), i.e., 
surface expression of IgE and c-kit as well as strong meta-
chromatic staining. Moreover, we analyzed the presence 
of individual MC proteases at the protein level and found 
significant amounts of mMCP-4, -5, -6 and MC-CPA in WT 
PCMCs. As PCMCs contain all types of MC proteases, they 
resemble those MCs found in tissues involved in allergic 
inflammation, e.g., in the skin, in murine lungs and in the 
smooth muscle layer around airways of asthmatic patients 
(Bradding et al. , 2006 ; Waern et al. , 2009 ). 
 In this study, we found that MC-mediated degrada-
tion of IL-13 was completely dependent on the presence 
of serglycin proteoglycan. This was demonstrated by the 
inability of serglycin −/− MCs to reduce IL-13 levels upon 
degranulation induced by Fc ɛ RI crosslinking or calcium 
ionophore. A plausible explanation for this finding was 
that the lack of a number of preformed MC proteases in 
serglycin −/− MCs caused their inability to degrade IL-13. 
Another possibility is that the reduction in IL-13 levels was 
merely due to binding of added IL-13 to serglycin proteo-
glycan on the cell surface, resulting in reduced levels in 
supernatants. We therefore assessed the involvement of 
proteolytic cleavage by using a panel of protease inhibi-
tors, and showed that a serine protease inhibitor could 
prevent IL-13 reduction, whereas inhibitors of metallo-
proteases, cysteine proteases and aspartic acid proteases 
had no effect. Taken together, these findings strongly 
suggested that the IL-13 reduction seen in Fc ɛ RI-activated 
murine MCs is due to proteolytic events, mediated by one 
or several serglycin-dependent serine proteases expressed 
by murine MCs, i.e., by mMCP-4, -5, -6 or by other as yet 
non-identified proteases that rely on serglycin for storage. 
 Considering the protective role of mMCP-4 in the aller-
gic airway inflammation that we reported earlier (Waern et 
al. , 2009 ), it was of particular interest to evaluate the con-
tribution of mMCP-4 to IL-13 degradation. We noticed that 
mMCP-4 −/− MCs did not degrade endogenously produced 
IL-13 as efficiently as did WT MCs, whereas there was only 
a minor difference between mMCP-4 −/− and WT MCs in 
the ability to degrade exogenously added IL-13. mMCP-4 
can thus promote IL-13 degradation, a finding that is in 
 Figure 7   Cathepsin G and granzyme B in IL-13 degradation. 
 (A) Recombinant murine IL-13 (1  μ g) was incubated for 3 h with either recombinant murine granzyme B (0.2  μ g) or human cathepsin G (0.2 
 μ g) as indicated, followed by SDS-PAGE and Coomassie brilliant blue staining. (B) PCMCs from WT, mMCP-4 −/− , MC-CPA −/− , MC-CPAmut and 
serglycin −/− mice were analyzed for levels of cathepsin G protein using Western blot analysis. β-Actin was used as a loading control. (C) WT 
PCMCs, either control (gray bars) or activated with IgE  + antigen (IgE/Ag; black bars), were incubated with recombinant murine IL-13 (10 
ng)   ±  1 or 10  μ m of an inhibitor of human cathepsin G as indicated. Residual levels of IL-13 after 24 h were measured using ELISA. *,  p  <  0.05; 
**,  p  <  0.01; ***,  p  <  0.001 .
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 Figure 8   IL-13 degradation by MCs requires functional heparin and is partly cell bound. 
 (A) WT PCMCs were degranulated by IgE crosslinking (IgE/Ag). IL-13 was either added to medium alone, to cell-free supernatants from 
degranulated cells (sup) or to whole cultures containing both cells and supernatants and incubated for 24 h. (B) , WT PCMCs were degranu-
lated by IgE crosslinking (IgE/Ag) or by calcium ionophore (A23187) in the presence of IL-13. Protamine, a heparin antagonist, was added as 
indicated. IL-13 levels were analyzed by ELISA and are shown as means  ±  SEM (n  =  3). 
agreement with previous studies showing that human 
chymase has the ability to degrade IL-13 (Zhao et al. , 2005 ). 
However, it is important to emphasize that the absence of 
mMCP-4 resulted in only a partial blockade of IL-13 degra-
dation, which suggests the contribution of other (sergly-
cin-dependent) MC serine proteases to the total impact of 
MCs on IL-13 levels. We may therefore envisage a scenario 
in which multiple serglycin-dependent proteases may 
act on IL-13 and, most likely, on other pro-inflammatory 
cytokines as well, thereby serving a regulatory function by 
preventing accumulation of excessive amounts of poten-
tially harmful cytokines. Accordingly, the absence of indi-
vidual serglycin-dependent proteases (e.g., mMCP-4, -6) 
may result in only limited effects (or no effects) on total 
cytokine-degrading capacity due to redundancy and over-
lapping functions among individual serglycin-dependent 
proteases, whereas a global absence of the serglycin-
protease axis will lead to a profound impairment in the 
ability of MCs to regulate cytokines such as IL-13. 
 As shown here, MCs have the capacity both to gene-
rate and to degrade IL-13, which raises the intriguing 
question of whether MCs are net producers or degraders 
of IL-13. Although we cannot with certainty clarify this 
issue, it is conceivable that IL-13 generation and degrada-
tion, respectively, may occur during different timeframes 
during an inflammatory reaction. Conceivably, IL-13 pro-
duction and release into the exterior may occur in the 
early phase of an inflammatory response, whereas IL-13 
degradation is a subsequent event serving to prevent 
excessive effects of secreted IL-13. 
 An intriguing finding of this study was that IL-13 
degradation was completely dependent on the presence 
of MC-CPA protein. However, a role for MC-CPA catalytic 
activity in the degradation process was excluded as MCs 
expressing inactive MC-CPA or MCs treated with a metallo-
protease inhibitor exhibited essentially normal IL-13 deg-
radation. These findings, together with the total blockade 
of IL-13 degradation by a serine protease inhibitor, suggest 
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that the putative IL-13-degrading proteases are strictly 
dependent on the presence of MC-CPA at the protein level. 
However, the exact nature of the IL-13-degrading protease 
activity is still intriguing. 
 Several reports suggest that MC proteases, in particu-
lar chymases, are dependent on interaction with heparin 
(serglycin) for optimal proteolysis of certain substrates. 
The mechanism for this effect involves simultaneous 
binding of the MC protease and its substrate to the same 
heparin (serglycin) molecule. Thereby, the heparin chain 
will bring the enzyme and substrate in close contact and 
in this way facilitate proteolytic cleavage. In line with 
this notion, heparin has been shown to preferentially 
facilitate the cleavage of heparin (serglycin)-binding sub-
strates, e.g., fibronectin and thrombin (Tchougounova 
et al. , 2001 ; Tchougounova and Pejler , 2001 ). To evalu-
ate whether such a mechanism is operative in the MC-
mediated degradation of IL-13, we used a polycationic 
heparin antagonist (protamine) that blocks the anionic 
sites of the serglycin moiety of the putative serglycin-MC 
protease complex without affecting the active site of the 
putative IL-13-degrading protease(s). Indeed, protamine 
was shown to inhibit the degradation of IL-13, which sug-
gests that IL-13 degradation is facilitated by the simulta-
neous binding of IL-13 and IL-13-degrading MC proteases 
to serglycin. This scenario would thereby imply that IL-13 
has the ability to interact with heparin, a notion that 
may be supported by the previously reported ability of 
heparin to modulate IL-13-mediated activities (Kanabar 
et al. , 2008 ). 
 The interaction between MC proteases and the heparin 
side chains of serglycin proteoglycan may also influence 
the location of proteases in the extracellular environment 
when released upon degranulation, e.g., proteases with 
strong binding to heparin would be localized close to the 
MC or even bound to the cell surface, whereas those with 
weaker binding would be allowed to diffuse away from the 
MC surface. In support of such a scenario, our data suggest 
that the IL-13-degrading proteases are partly attached to 
the cell surface upon MC degranulation. This notion is 
also supported by previous studies showing that mMCP-6 
(Ghildyal et al. , 1996 ) and mMCP-4 (Tchougounova 
and Pejler , 2001 ), both of which have high affinity for ser-
glycin (Pejler and Maccarana , 1994 ; Hallgren et al. , 2004 ), 
remain largely associated with the cell surface after MC 
degranulation. 
 In summary, the present findings implicate sergly-
cin and its complex-bound proteases in down-regulating 
extracellular levels of pathogenic cytokines. Conceivably, 
the serglycin-protease axis may have a major impact on 
the outcome of inflammatory processes in which MCs 
participate, by limiting excessive effects of cytokines 
expressed either intrinsically by MCs or by other inflam-
matory cells. 
 Materials and methods 
 Mice 
 Serglycin −/− ( Å brink et al., 2004 ), mMCP-4 −/− (Tchougounova et al. , 
2003 ), mMCP-6 −/− (Shin et al. , 2008 ) and MC-CPA −/− (Feyerabend 
et al. , 2005 ) mice, all on a C57BL/6 genetic background, were previ-
ously described. Mc-cpa Y356L,E378A (MC-CPAmut) are knock-in mice with 
catalytically inactive MC-CPA (Schneider et al. , 2007 ). WT C57BL/6 
mice were used as controls. Mice were bred and maintained in Upp-
sala Biomedical Centre. Animal experiments were approved by the 
local ethics committee. 
 Generation of PCMCs 
 Peritoneal cell-derived MCs (PCMCs) were established according 
to a protocol described by Malbec et al.  (2007) ). In short, PCMCs 
were established by culture of peritoneal cells in DMEM plus Glu-
taMAX (Gibco, Invitrogen, Paisley, UK) supplemented with 10 % 
supernatant of stem cell factor-transfected Chinese hamster ovary 
cells (a gift from Dr. M. Daeron, Pasteur Institute, France), 10 % 
FBS, 60  μ g/ml streptomycin, 50  μ g/ml penicillin, 100  μ m MEM 
non-essential amino acids and 50  μ m 2-mercaptoethanol (Gibco). 
The medium was changed every 4 to 5 days. Cultures of 4 – 5 weeks 
were used for all experiments. 
 Cytospin and staining 
 Cells were collected on cytospin slides (600 rpm for 5 min on a Cyto-
spin 2, Shandon Southern Products Ltd, Runcorn, UK). Slides were 
stained for 5 min in concentrated May-Gr ü nwald (Merck, Darmstadt, 
Germany) and for 1 min in a 2-fold dilution of May-Gr ü nwald followed 
by 15 min in 2.5 % Giemsa (Merck). For metachromatic staining, slides 
were placed in a 2 % toluidine blue solution (Sigma Aldrich, St Louis, 
MO, USA) containing 1 % sodium chloride (pH 2.4). Aft er staining, the 
slides were washed in H 2 O and air-dried. 
 Flow cytometry 
 Flow cytometry was used to analyze cell surface expression of CD117 
and Fc ɛ RI on PCMCs. WT PCMCs were cultured overnight in the pres-
ence of 5  μ g/ml murine IgE anti-TNP (BD Biosciences Pharmingen, San 
Jose, CA, USA) to saturate unbound Fc ɛ RI. Samples of 0.5×10 6 cells 
in PBS containing 0.5 % FBS were stained for 30 min on ice with 0.5 
 μ g FITC-labeled rat anti-mouse IgE, PE-labeled rat anti-CD117 or with 
rat isotype controls (ImmunoTools, Friesoythe, Germany). Cells were 
washed twice and then analyzed using a FACScan flow cytometer and 
the CELLQuest 3.3 soft ware (Becton Dickinson, San Jose, CA, USA). 
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 Western blot analyses 
 Western blot was performed as previously described (Waern et al. , 
2010 ). Briefly, cell extracts from PCMCs were separated under reduc-
ing conditions on 12 % SDS-PAGE gels and blotted onto polyvinylidene 
difluoride membranes. Aft er blocking, membranes were stained over 
night at 4 ° C with rabbit antisera towards mMCP-4, mMCP-5, mMCP-
6, MC-CPA or cathepsin G (dilution 1:400 in LI-COR blocking buff er, 
LI-COR Biosciences, Cambridge, UK). As a loading control,  β -actin 
was detected using a goat polyclonal IgG (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA, dilution 1:200). Bound primary antibodies were 
detected with IR Dye 800-conjugated donkey anti-rabbit Ig or IR Dye 
800-conjugated donkey anti-goat Ig (LI-COR Biosciences, dilution 
1:1000). Visualization was performed using Odyssey IR imaging sys-
tem (LI-COR Biosciences). 
 IL-13 degradation 
 PCMCs were degranulated via crosslinking of Fc ɛ RI. IgE anti-TNP 
(BD Biosciences Pharmingen) was added to 1×10 6 PCMCs at a con-
centration of 1  μ g/ml followed by incubation overnight at 37 ° C. 
Cells were washed three times and resuspended with DMEM 
supplemented as above. Ovalbumin (OVA)-TNP was added to a 
fi nal concentration of 0.4  μ g/ml to 1×10 6 cells/ml. For calcium 
ionophore-mediated degranulation, A23187 (Sigma Aldrich) was added 
(2  μ m fi nal concentration) to 1×10 6 cells/ml. Mouse recombinant inter-
leukin-13 (mrIL-13) (PeproTech, London, UK) was added at 2 – 10 ng/ml 
to the PCMCs immediately aft er stimulation with either IgE anti-TNP, 
A23187 or to non-stimulated control cells. As an additional control, 
IL-13 was added to wells containing medium without cells. No external 
IL-13 was added when degradation of endogenous IL-13 was analyzed. 
Experiments were performed in triplicate and supernatants were col-
lected at 1, 4 and 24 h aft er stimulation. To assess the localisation of 
IL-13 degradation, supernatant from IgE anti-TNP-stimulated MCs was 
separated from cells by centrifugation and incubated with 2 ng/ml mrIL-
13 for 24 h. 
 Detection of IL-13 
 Levels of IL-13 were analyzed by ELISA according to the manufac-
turer ’ s instructions (PeproTech). In a separate experiment, IL-13 was 
detected by Western blot analyses using rabbit anti-murine IL-13 
(PeproTech). 
 Protease inhibitors and heparin antagonist 
 PCMCs were degranulated with IgE crosslinking or A23187 in the 
presence of exogenous IL-13 with the following inhibitors added to 
separate wells: 2 mm Pefabloc SC (Pentapharm LTD, Basel, Swit-
zerland), 10 mm EDTA (Merck), 20  μ m E-64 (Boehringer Mannheim 
Biochemicals, Mannheim, Germany), 10  μ g/ml Pepstatin A (USB, 
Cleveland, OH, USA) or 10  μ m Cathepsin G Inhibitor I (Merck). To 
block heparin, protamine (Sigma) was added at three diff erent con-
centrations (2.5, 25 and 250  μ g/ml). Supernatants were collected at 
1, 4 and 24 h aft er stimulation and analyzed by IL-13 ELISA. 
 Generation and analyses of recombinant 
mMCP-5 
 A region encoding a six-histidine tag and an enterokinase site was 
added to the 5 ′ end of the coding region of mMCP-5. The sequence 
was ordered from Genscript Corporation (Piscataway, NJ, USA) as a 
fragment inserted in the vector pUC 57, with EcoRI and XhoI sites in 
the 5 ′ and 3 ′ ends, respectively. This fragment was excised from the 
vector by cleavage with EcoRI and XhoI and inserted in the mam-
malian expression vector pCEP-Pu2 (Vernersson et al. , 2002 ). Fol-
lowing transfection of this construct into HEK-293 EBNA cells and 
selection with puromycin (1.5  μ g/ml fi nal concentration), a producer 
cell line was obtained. This cell line secreted inactive histidine-
tagged mMCP-5 into the conditioned medium and the recombinant 
protein could be purifi ed on IMAC Ni chelating columns (Qiagen, 
Hilden, Germany). A more detailed description of transfection and 
purifi cation procedures can be found in Andersson et al.  (2009 , 
2010). To obtain an enzymatically active mMCP-5, the protease 
was cleaved with enterokinase for 3 h at 37 ° C. (Roche Diagnostics, 
Mannheim, Germany). Following enterokinase cleavage, the activity 
of the enzyme was tested against a new type of recombinant sub-
strate containing a cleavable sequence inserted in a linker region 
between two thioredoxin proteins. The enzyme cleaves in the linker 
region and generates two fragments of approximately 12 kDa in 
size (Figure 6A). The extent of cleavage can be monitored by SDS-
PAGE analysis. Based on our previous analysis by phage display of 
the rat counterpart of mMCP-5 (rMCP-5) (Karlson et al. , 2003 ), we 
constructed four diff erent recombinant substrates with the follow-
ing cleavable linker sequences: VLL V SEVL, VLL I SEVL, VLL A SEVL and 
VLL F SEVL. The fi rst three of these four are elastase substrates with 
valine, isoleucine or alanine in the cleavable position, whereas the 
fourth substrate is a chymase substrate with a phenylalanine in the 
cleavable position. All four recombinant proteins were produced in 
 E.coli Rosetta gami cells, and the protein was purifi ed on Ni chelating 
columns according to previously published procedures (Andersson 
et al. , 2009, 2010 ). 
 Statistical analysis 
 Statistical signifi cance was calculated with Student ’ s  t -test, using 
the GraphPad Prism 4.0 (GraphPad Soft ware, Inc, San Diego, CA, 
USA). All p-values   <  0.05 were considered to be signifi cant. 
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